Neural transplantation (auto-adrenal, fetal nigral and fetal adrenal) in Parkinson's disease: the Mexican experience.

Department of Neurosurgery, Centro Medico La Raza, Mexico City, Mexico.
Progress in brain research (Impact Factor: 5.1). 02/1990; 82:593-602.
Source: PubMed
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: the aim of this systematic review is to evaluate the scientific production on Parkinson’s disease held in Mexico. Methods: we conducted a systematic search of publications in Mexico at the following sites: Medline via PubMed, Mexican Index of Latin American Biomedical Journals (IMBIOMED), Articles Published in Mexico´s Health Information System (ARTEMISA), Scientific Electronic Library Online Mexico (SciELO) and Medigraphic. Results: through the search protocol in PubMed and the established criteria a total of 113 publications from January 1998 thru December 2010 were obtained. An additional 34 publications were obtained from the other indexes consulted. Approximately sixty percent of all publications corresponded to the basic research area. The number of publications by year increased noticeably since 2005. Conclusion: the basic research markedly exceeds the clinical research thus indicating a need to increase the interest and importance of clinical studies in mexican patients with Parkinson’s disease. In terms of publications in mexican journals a greater number of clinical original work is required as opposed to the number of reviews of the literaure currently available.
  • Source
    BMJ Clinical Research 10/1990; DOI:10.1136/bmj.301.6756.874-a · 14.09 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The pathological hallmark of Parkinson�s disease is a gradual loss of nigrostriatal dopamine-containing neurons, which is responsible for the cardinal motor symptoms of the disease. Current therapeutic strategies are mostly based on pharmacological enhancement of dopaminergic neurotransmission. This therapeutic approach has several long-term side effects, such as dyskinesias and fl uctuations of response, and is therefore limited in its use. Transplantation of fetal dopaminergic precursor cells has provided the proof that a cell replacement therapy can ameliorate clinical symptoms in affected patients. Novel therapies aiming at a stimulation of an endogenous dopamine production within the brain at a continuous rate might provide a more physiological and elegant way to overcome the dopaminergic defi ciency in parkinsonian brains. This article will review recent studies demonstrating the potential of these alternative cell graft sources for treating Parkinson�s disease. En la enfermedad de Parkinson, las neuronas dopaminérgicas de la sustancia nigra degeneran, lo que trae como consecuencia un défi cit de dopamina en sus áreas de proyección. Estas alteraciones histológicas y neuroquímicas se traducen en la mayoría de los trastornos motores que presentan los pacientes parkinsonianos. Las estrategias terapéuticas actuales se basan en fármacos que mejoran la neurotransmisión dopaminergica. Este enfoque terapéutico tiene efectos secundarios a largo plazo, como fl uctuaciones de la respuesta motora y discinesias. El trasplante de células dopaminérgicas fetales ha demostrado una mejoría de los síntomas clínicos. Actualmente, se desarrollan nuevas estrategias terapéuticas para estimular un reemplazo neuronal endógeno a partir de precursores neuronales presentes en el cerebro adulto. Este trabajo resume los estudios que muestran el potencial de la terapia celular en la enfermedad de Parkinson.
    Revista de medicina de la Universidad de Navarra 12/2007; 52(2):17-24.